Oxonol, MGM-15 and DEA Scheduling: July 2026 Status
DEA’s July 2026 action is relevant to Oxonol because the product’s manufacturer identifies MGM-15 in the formula. The federal document names MGM-15, not the retail brand. It is currently a notice of intent rather than an effective temporary scheduling order.
The July 6 document is a notice of intent
DEA published its MGM-15 notice in the Federal Register on July 6, 2026. The agency states that it intends to temporarily place MGM-15, MGM-16, and mitragynine pseudoindoxyl in Schedule I. The same document says the order will not be issued before August 5, 2026 and will take effect when the later order is published.
Those procedural words matter. “DEA intends to schedule” is accurate for the present stage. “DEA has already scheduled MGM-15” is premature unless and until the effective order appears.
Why the brand name does not decide coverage
Federal scheduling documents identify substances, their chemical names, and covered forms. They cannot be expected to list every retail brand. The manufacturer says Oxonol is its brand name for tablets containing MGM-15 and mitragynine. Therefore the useful question is whether the current product contains the named substance MGM-15, not whether “Oxonol” appears in the notice.
What DEA says MGM-15 is
The notice identifies MGM-15 as dihydro-7-hydroxymitragynine. It describes MGM-15, MGM-16, and mitragynine pseudoindoxyl as synthetic derivatives of plant alkaloids and says MGM-15 is produced through synthetic modification of purified mitragynine isolates or 7-hydroxymitragynine. The document separately acknowledges mitragynine and 7-hydroxymitragynine as naturally occurring in the plant.
How this relates to the separate 7-OH action
DEA issued two related notices. One addresses 7-OH above specified thresholds. The other addresses MGM-15, MGM-16, and mitragynine pseudoindoxyl. Describing a formulation as structurally different from 7-OH does not answer whether it is addressed by the companion MGM-15 notice.
DEA’s July 1 announcement names all four substances and explains that the future controls begin once the temporary orders take effect. The Federal Register document supplies the detailed timing for MGM-15 and the related substances.
What should be checked next
- Federal order: look for a later Federal Register temporary scheduling order on or after August 5, 2026.
- Current formula: verify whether the manufacturer continues to identify MGM-15 in Oxonol.
- State and local rules: federal timing does not replace jurisdiction-specific checks.
- Inventory and records: businesses should preserve invoices, labels, formulas, lot records, and dated legal guidance.
Where MIT fits
MIT means mitragynine and is not named among the three substances in the MGM-15 notice. It is a separate naturally occurring alkaloid identity, even when concentrated into an extract. That does not make an MIT product FDA approved or exempt from every possible rule. It does make MIT different from an MGM-15 formulation at the ingredient level.
Kratom Paradise’s MIT tablets and powders are labeled and organized around mitragynine, not Oxonol or an MGM-series derivative. For buyers focused on a clear named ingredient, consistent tablet or powder format, and qualified documentation, that is a more direct product path than treating a newly branded MGM-15 formulation as interchangeable with MIT.
Keep the status dated
This article reflects the public record reviewed July 14, 2026. Visit the Kratom Paradise scheduling tracker and the government sources before relying on it later. You can also read What is Oxonol? and our Oxonol vs MIT vs 7-OH comparison.
This article is educational product and regulatory information, not medical or legal advice.